Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease

Integrated Blood Pressure Control

Volumn 6, Issue , 2013, Pages 101-109

  Chandy, Dipak ^a   Aronow, Wilbert S ^a   Banach, Maciej ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antihypertensive drugs; Blood pressure; COPD; Hypertension; Treatment

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL; PINDOLOL; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; TRIAMTERENE; UNINDEXED DRUG; VALSARTAN;

BLOOD PRESSURE REGULATION; BRONCHODILATATION; BRONCHOSPASM; CARDIOSELECTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; COUGHING; DRUG ANTAGONISM; DRUG TOLERABILITY; EXPIRATORY FLOW RATE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; HYPOKALEMIA; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LOW DRUG DOSE; METABOLIC ALKALOSIS; MORBIDITY; MORTALITY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

EID: 84880106247     PISSN: None     EISSN: 11787104     Source Type: Book Series    
DOI: 10.2147/IBPC.S33982     Document Type: Review

References (78)

1. Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(46):938-943.
2. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Survell Summ 2002;51(6):1-16.
3. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20): 2043-2050.
4. Burt VL, Whelton P, Roccella EJ, etal. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25: 305-313.
5. Wells KB, Stewart A, Hays RD, etal. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262(7):914-919.
6. Chobanian AV, Bakris GL, Black HR, etal; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
7. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham study. Am Heart J. 1983;105(2): 311-315.
8. Higgins M, Keller JB, Wagenknecht LE, etal. Pulmonary function and cardiovascular risk factor relationships in black and in white young men and women. The CARDIA Study. Chest. 1991;99(2):315-322.
9. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. Am Rev Respir Dis. 1989;140(3 Pt 2):S56-S63.
10. Aronow WS, Fleg JL, Pepine CJ, etal. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037-2114.
11. Beckett NS, Peters R, Fletcher AE, etal; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
12. Aronow WS. Hypertension guidelines. Hypertension. 2011;58: 347-348.
13. Banach M, Michalska M, Kjeldsen SE, Małyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12: 1835-1844.
14. Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121:253-258.
15. Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 2012;21:3-5.
16. Banach M, Aronow WS. Hypertension therapy in the elderly-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens. 2012;26:641-643.
17. Aronow WS. Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly. Am J Therap. Epub July 15, 2011.
18. Appel LJ. The verdict from ALLHAT-thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002;288(23):3039-3042.
19. Herrin MA, Feemster LC, Crothers K, Uman JE, Bryson CL, Au DH. Combination antihypertensive therapy among patients with COPD. Chest. 2013;143(5):1312-1320.
20. Light RW, Chetty KG, Stansbury DW. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease. Am J Med. 1983;75(4A):109-114.
21. Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med. 1989;86(6 Pt 1):653-657.
22. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet. 1990;336(8728): 1396-1399.
23. Bear R, Goldstein M, Phillipson E, etal. Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med Assoc J. 1977;117(8):900-903.
24. Raghavan N, Webb K, Amornputtisathaporn N, O'Donnell DE. Recent advances in pharmacotherapy for dyspnea in COPD. Curr Opin Pharmacol. 2011;11(3):204-210.
25. Heran BS, Chen JM, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev. 2012;11:CD008167.
26. Brown MJ, Palmer CR, Castaigne A, etal. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366-372.
27. Chapman N, Dobson J, Wilson S, etal; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007; 49(4):839-845.
28. Václavík J, Sedlák R, Plachy M, etal. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069-1075.
29. Kuster GM, Kotlyar E, Rude MK, etal. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111(4):420-427.
30. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis. 1985;132(3):541-547.
31. McGavin CR, Williams IP. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest. 1978;72(4):327-332.
32. Ling Y, Saleem W, Shee CD. Concomitant use of beta-blockers and beta2-agonists. Eur Respir J. 2008;31(4):905-906.
33. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005;98(7):493-497.
34. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339(8):489-497.
35. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.
36. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715-725.
37. van Gestel YR, Hoeks SE, Sin DD, etal. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178(7): 695-700.
38. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10): 880-887.
39. Ekström MP, Hermansson A, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715-720.
40. Dorow P, Thalhofer S, Bethge H, Disselhoff G, Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol. 1990;16 Suppl 5:S36-S44.
41. Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol. 1976;3(6):1007-1014.
42. Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol. 1986;8 Suppl 11: S74-S77.
43. Dorow P, Bethge H, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol. 1986;31(2):143-147.
44. Cockcroft JR, Pedersen ME. β-blockade: benefits beyond blood pressure reduction? J Clin Hypertens (Greenwich). 2012;14(2):112-120.
45. Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009;3(4):329-334.
46. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol. 2010;8(6):733-741.
47. Stepień M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol. 2010;8(6):747-752.
48. Basso A, Piantanelli L, Cognini G, Giunta S, Andreoni A, Paciaroni E. Acebutolol-induced decrease of mononuclear leukocyte beta-adrenoceptors in hypertension. Pharmacology. 1985;31(5):278-283.
49. Jakubetz J, Schmuck S, Poller U, etal. Cardiac effects of beta-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans: beta1-and/or beta2-adrenoceptor mediated? J Cardiovasc Pharmacol. 1999;33(3):461-472.
50. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta-and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2004;44(3):497-502.
51. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21(12):1290-1295.
52. Jabbour A, Macdonald PS, Keogh AM, etal. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780-1787.
53. Guazzi M, Agostoni P, Matturri M, Pontone G, Guazzi MD. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J. 1999;138(3 Pt 1):460-467.
54. George RB, Manocha K, Burford JG, Conrad SA, Kinasewitz GT. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest. 1983;83(3):457-460.
55. Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging. 2008;25(2):131-144.
56. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234-242.
57. Bucknall CE, Neilly JB, Carter R, Stevenson RD, Semple PF. Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed). 1988;296(6615): 86-88.
58. Boulet LP, Milot J, Lampron N, Lacourcière Y. Pulmonary function and airway responsiveness during long-term therapy with captopril. JAMA. 1989;261(3):413-416.
59. Mortensen EM, Copeland LA, Pugh MJV, etal. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
60. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012;123(8):487-498.
61. Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax. 2003;58(7):629-631.
62. Tanaka H, Teramoto S, Oashi K, etal. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation. 2001;104(3): 281-285.
63. Andreas S, Herrmann-Lingen C, Raupach T, etal. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J. 2006;27(5):972-979.
64. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554-2560.
65. Melot C, Hallemans R, Naeije R, Mols P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1984;130(4):612-616.
66. Bratel T, Hedenstierna G, Nyquist O, Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. Eur Respir J. 1990;3(1):46-54.
67. Schwartzstein RS, Fanta CH. Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic. Am Rev Respir Dis. 1986;134(2):262-265.
68. Ann Twiss M, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as maintenance therapy for asthma. Br J Clin Pharmacol. 2002;53(3):243-249.
69. Patakas D, Maniki E, Tsara V, Dascalopoulou E. Nifedipine treatment of patients with bronchial asthma. J Allergy Clin Immunol. 1987;79(6): 959-963.
70. Itskovitz HD. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther. 1994;16(3):490-504.
71. Biernacki W, Flenley DC. Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. J Hum Hypertens. 1989;3(6):419-425.
72. Dinh Xuan AT, Matran R, Regnard J, Vitou P, Advenier C, Lockhart A. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects. Br J Clin Pharmacol. 1988;26(6): 703-708.
73. Crain D, Bhat A. Current treatment options in smoking cessation. Hosp Pract (1995). 2010;38(1):53-61.
74. Corriveau ML, Vu-Dinh Minh, Dolan GF. Long-term effects of hydralazine on ventilation and blood gas values in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Med. 1987;83(5):886-892.
75. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50.
76. Mathew J, Aronow WS, Chandy D. Therapeutic options for severe asthma. Arch Med Sci. 2012;8(4):589-597.
77. Sekhri V, Mehta N, Rawat N, Lehrman SG, Aronow WS. Management of massive and nonmassive pulmonary embolism. Arch Med Sci. 2012;8(6):957-969.
78. Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M. Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci. 2011;7(6): 1055-1066.